William L. Trepicchio

4.8k citations

61 papers · 3.2k indexed · 1 hit paper · h-index 26

Immunology top 1%
Molecular Biology top 10%
Oncology top 5%
Dermatology top 0.5%
Hematology top 2%

Co-authors: Andrew J. Dorner James G. Krueger Debra D. Pittman Judith Oestreicher Frank Wang Edmund Lee Francesca Chamian Madhav V. Dhodapkar
Topics: Lymphoma Diagnosis and Treatment (11 papers)Cytokine Signaling Pathways and Interactions (10 papers)Cancer Genomics and Diagnostics (8 papers)
Cited by: Immunology Dermatology Hematology
Journals: Nucleic Acids Research Journal of Clinical Investigation The Journal of Experimental Medicine
Partner nations: United States Italy United Kingdom

In The Last Decade

William L. Trepicchio

59 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris

2004 738 citations Edmund Lee, William L. Trepicchio et al. The Journal of Experimental Medicine profile →

Peers

Countries citing papers authored by William L. Trepicchio

Since Specialization

Citations

This map shows the geographic impact of William L. Trepicchio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William L. Trepicchio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William L. Trepicchio more than expected).

Fields of papers citing papers by William L. Trepicchio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William L. Trepicchio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William L. Trepicchio. The network helps show where William L. Trepicchio may publish in the future.

Co-authorship network of co-authors of William L. Trepicchio

This figure shows the co-authorship network connecting the top 25 collaborators of William L. Trepicchio. A scholar is included among the top collaborators of William L. Trepicchio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William L. Trepicchio. William L. Trepicchio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON‐1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC 2019 ·Hematological Oncology ·John Radford,Joseph M. Connors,Anas Younes,Andrea Gallamini,Stephen M. Ansell,(unknown),June‐Won Cheong,Ian W. Flinn,Nagesh Kalakonda,Mark Kaminski,Ruth Pettengell,Matthew Onsum,Neil C. Josephson,Shingo Kuroda,(unknown),Harry Miao,Ashish Gautam,William L. Trepicchio,Anna Sureda	0
2	Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility 2017 ·JMIR Research Protocols ·(unknown),Steven A. Eschrich,Anders Berglund,Melissa Mitchell,David Fenstermacher,Hadi Danaee,Hongyue Dai,Daniel M. Sullivan,William L. Trepicchio,William S. Dalton	5
3	Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers 2017 ·PLoS ONE ·Hadi Danaee,Thea Kalebic,Timothy Wyant,Matteo Fassan,Claudia Mescoli,Feng Gao,William L. Trepicchio,Massimo Rugge	27
4	262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study 2017 ·Journal of Investigative Dermatology ·(unknown),Sean Whittaker,Steve Horwitz,Madeleine Duvic,Reinhard Dummer,Julia Scarisbrick,Pietro Quaglino,Pier Luigi Zinzani,Pascal Wolter,(unknown),Maria Corinna Palanca-Wessels,Erin Zagadailov,William L. Trepicchio,Huamao Mark Lin,Melissa H. Little,H. Miles Prince	1
5	Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib 2015 ·PLoS ONE ·Бин Ли,Hyunjin Shin,(unknown),(unknown),Yuri Nikolsky,Andrew Hope,Marina Bessarabova,Matthew Schu,(unknown),David Merberg,Andrew J. Dorner,William L. Trepicchio	30
6	Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial 2010 ·Leukemia & lymphoma ·André Goy,Steven H. Bernstein,Alice McDonald,Michael D. Pickard,Hongliang Shi,Mark D. Fleming,Barbara M. Bryant,William L. Trepicchio,Richard I. Fisher,Anthony Boral,George Mulligan	19
7	Validation of a flow cytometry based G2M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition 2010 ·Journal of Immunological Methods ·Jose Estevam,Hadi Danaee,Ray Liu,Jeffrey Ecsedy,William L. Trepicchio,Timothy Wyant	12
8	A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer 2009 ·Journal of Thoracic Oncology ·Thomas J. Lynch,David Fenton,Vera Hirsh,David Bodkin,Edward L. Middleman,Alberto Chiappori,Balázs Halmos,Reyna Favis,Hua Liu,William L. Trepicchio,Omar Eton,Frances A. Shepherd	52
9	Designing prospective clinical pharmacogenomic (PG) trials: meeting report on drug development strategies to enhance therapeutic decision making 2006 ·The Pharmacogenomics Journal ·William L. Trepicchio,David M. Essayan,Susan T. Hall,Geraldine P. Schechter,Živana Težak,(unknown),David M. Weinreich,Richard Simon	8
10	A Single Administration of Recombinant Human Interleukin‐12 Is Associated With Increased Expression Levels of Interferon‐gamma and Signal Transducer and Activator of Transcription in Healthy Subjects 2005 ·The Journal of Clinical Pharmacology ·(unknown),Monette Cotreau,(unknown),Kevin Dykstra,Judy Oestreicher,Andrew Strahs,Andrew J. Dorner,Victor H. Van Cleave,William L. Trepicchio,Ullrich Schwertschlag	5
11	Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgarisbreakdown → 2004 ·The Journal of Experimental Medicine ·Edmund Lee,William L. Trepicchio,Judith Oestreicher,Debra D. Pittman,Frank Wang,Francesca Chamian,Madhav V. Dhodapkar,James G. Krueger	738
12	Narrowband (312-nm) UV-B Suppresses Interferon γ and Interleukin (IL) 12 and Increases IL-4 Transcripts 2003 ·Archives of Dermatology ·Ian Walters,Maki Ozawa,Irma Cardinale,Patricia Gilleaudeau,William L. Trepicchio,(unknown),James G. Krueger	73
13	Interleukin-11 Modulates Th1/Th2 Cytokine Production from Activated CD4 ⁺ T Cells 2001 ·Journal of Interferon & Cytokine Research ·(unknown),(unknown),Andrew J. Dorner,William L. Trepicchio	73
14	Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling 2001 ·The Pharmacogenomics Journal ·Judy Oestreicher,Ian Walters,Toyoko Kikuchi,Patricia Gilleaudeau,(unknown),Ullrich Schwertschlag,Andrew J. Dorner,James G. Krueger,William L. Trepicchio	148
15	Interleukin-11 reduces T-cell-dependent experimental liver injury in mice 1999 ·Hepatology ·(unknown),(unknown),(unknown),Jamie Erickson,(unknown),Page Bouchard,Andrew J. Dorner,William L. Trepicchio	60
16	Interleukin‐11: A gp130 Cytokine 1998 ·Annals of the New York Academy of Sciences ·William L. Trepicchio,Andrew J. Dorner	43
17	Recombinant Human Interleukin-11 Does Not Affect Functions of Purified Human Neutrophils In Vitro 1998 ·Journal of Interferon & Cytokine Research ·(unknown),(unknown),William L. Trepicchio,Mark A. Collins,Mark S. Klempner,Andrew J. Dorner	7
18	Upstream regulatory region of the human embryonic β-like globin gene, ϵ 1994 ·DNA sequence ·William L. Trepicchio,Michael A. Dyer,Ross C. Hardison,Margaret H. Baron	4
19	IGHminisatellite suppression of USF-binding-site- and Eμ-mediated transcriptional activation of the adenovirus major late promoter 1993 ·Nucleic Acids Research ·William L. Trepicchio,Theodore G. Krontiris	20
20	Members of therel/NF-χB family of transcriptional regulatory proteins bind theHRAS1minisatellite DNA sequence 1992 ·Nucleic Acids Research ·William L. Trepicchio,Theodore G. Krontiris	67

About William L. Trepicchio

William L. Trepicchio is a scholar working on Immunology, Dermatology and Cancer Research, having authored 61 papers that have together received 3.2k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (11 papers), Cytokine Signaling Pathways and Interactions (10 papers) and Cancer Genomics and Diagnostics (8 papers). The work is most often cited by research in Immunology (1.8k citations), Dermatology (606 citations) and Hematology (395 citations). William L. Trepicchio has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Andrew J. Dorner, James G. Krueger, Debra D. Pittman, Judith Oestreicher, Frank Wang, Edmund Lee, Francesca Chamian, Madhav V. Dhodapkar, K J Barrett and Patricia Gilleaudeau. Their work appears in journals such as Nucleic Acids Research, Journal of Clinical Investigation and The Journal of Experimental Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact